Gilead Sciences Archives

Malaysia 17 July 202017 July 2020

MOH said last November that 4,500 Malaysians were treated with generics of sofosbuvir.

Opinion 26 May 202026 May 2020

Compulsory licencing may not necessarily guarantee widespread access of remdesivir to Covid-19 patients in Malaysia.

Letter 22 May 202022 May 2020

Wall Street analysts suggest remdesivir could be priced between US5,000-US10,000 for a 10-day course of treatment.

Malaysia 21 May 202022 May 2020

Gilead Sciences has excluded Malaysia from receiving generic versions of remdesivir.

Malaysia 21 May 202022 May 2020

Three Opposition MPs say Malaysia can’t afford to spend as much on health care as Singapore or other Asian...

Malaysia 20 May 202021 May 2020

The only three Asean countries excluded by Gilead Sciences for generic versions of remdesivir in its new licencing agreements...

Letter 19 May 202019 May 2020

Gilead excluded Malaysia, among other middle-income countries, from distribution of Remdesivir to 127 nations under voluntary licensing.

World 12 May 202012 May 2020

Unwarranted high prices for medications could lead to preventable deaths, said a study.

World 20 April 202020 April 2020

The trial saw most patients with severe Covid-19 discharged within six days.

Tag: Gilead Sciences